Summary: For years, the buildup of toxic proteins in the brain has quietly preceded Alzheimer’s disease, often beginning decades before memory problems appear. Researchers at Washington University School of Medicine in St. Louis have developed a blood-based “biological clock” that uses a single test for the protein p-tau217 to predict when an individual is likely to begin showing cognitive symptoms.
By measuring plasma p-tau217, the model forecasts the likely age of symptom onset with a margin of error of about three to four years. This advance could transform how clinical trials are designed by identifying the optimal window for preventive therapies—before irreversible brain damage occurs—and may eventually help clinicians and patients plan individualized prevention strategies.
Key Facts
- “Tree ring” concept: The predictable accumulation of Alzheimer’s-related proteins in the brain and blood acts like tree rings, providing a chronological record of disease progression.
- Accuracy: The p-tau217 clock predicts age at symptom onset with an average error of three to four years.
- Age and resilience: Younger brains appear more resilient: if p-tau217 becomes elevated at age 60, symptoms may not appear for roughly 20 years; if elevation occurs at age 80, symptoms often appear in about 11 years.
- Accessibility: A blood test is far less costly and invasive than PET imaging or cerebrospinal fluid testing, increasing access for research and potential future clinical use.
- Clinical trial impact: The clock can help identify individuals likely to develop symptoms within a specified time frame, making preventive trials faster and more efficient.
Source: WUSTL
Researchers at Washington University School of Medicine in St. Louis have developed a method to predict when someone is likely to develop symptoms of Alzheimer’s disease using a single blood test.
In a study published Feb. 19 in Nature Medicine, the investigators showed that models based on plasma p-tau217 predicted symptom onset within a margin of three to four years. These findings have implications for selecting participants for preventive clinical trials and for future individualized risk planning.
More than 7 million Americans live with Alzheimer’s disease, and national costs for Alzheimer’s and other dementias are projected to be substantial. While a cure remains elusive, tools that predict when symptoms will begin could speed development of preventive treatments and improve planning for patients and families.
Protein forecasts symptom onset
The research was carried out as part of a project launched by the Foundation for the National Institutes of Health Biomarkers Consortium, a public‑private partnership that includes WashU Medicine. The clock models use p-tau217 measured in plasma—the liquid component of blood—to estimate the age when Alzheimer’s symptoms are likely to start.
Plasma p-tau217 is already used to help diagnose Alzheimer’s in people with cognitive impairment, though its routine use in cognitively unimpaired individuals is currently limited to research settings. The study analyzed longitudinal p-tau217 measurements from two long-running cohorts: the WashU Medicine Knight Alzheimer Disease Research Center (Knight ADRC) and the Alzheimer’s Disease Neuroimaging Initiative (ADNI). In total, the analysis included data from hundreds of older adults living independently in the community.
Plasma p-tau217 was measured with a clinically available diagnostic test (PrecivityAD2) and with additional assays used in the ADNI cohort. Prior studies have shown that plasma p-tau217 correlates strongly with amyloid and tau accumulation in the brain as detected by PET imaging—two misfolded proteins that are hallmark features of Alzheimer’s disease and begin accumulating many years before symptoms emerge.
The investigators describe the accumulation of amyloid and tau as analogous to tree rings: knowing when these markers become positive allows estimation of how close an individual is to developing clinical symptoms. The models produced median absolute errors of roughly 3.0 to 3.7 years in estimating the age of symptom onset. Importantly, the interval between p-tau217 positivity and symptom onset was shorter in older individuals, suggesting age-related differences in brain resilience or threshold for symptom expression.
The predictive approach proved robust across different p-tau217 assays, indicating generalizability. The authors made their modeling code available so other researchers can refine the models, and a web-based application was developed to explore the clock models further.
With continued refinement and validation, these blood-based clocks could improve the selection of participants for preventive clinical trials and, eventually, support individualized clinical care by estimating when symptoms are most likely to begin.
Key Questions Answered
Q: Is the “Alzheimer’s clock” test available now?
A: The p-tau217 test is clinically available for diagnosing people who already have memory problems, but it is not currently recommended for routine screening of healthy individuals outside of research. Scientists are using it to identify strong candidates for drug trials.
Q: Why is predicting symptom onset useful if there is no cure?
A: Prediction enables prevention. Knowing when symptoms are likely to start allows clinicians and researchers to intervene earlier with experimental therapies and gives families a concrete timeframe for planning care and support.
Q: Does a positive p-tau217 test mean I will definitely develop Alzheimer’s?
A: Elevated p-tau217 reflects accumulation of proteins strongly associated with Alzheimer’s and is a powerful predictor of future symptoms. However, prediction does not equal certainty, and the goal of this research is to use biomarker information to prevent or delay symptom onset.
Funding and support
This work was conducted under the FNIH Biomarkers Consortium project “Plasma Aβ and Phosphorylated Tau as Predictors of Amyloid and Tau Positivity in Alzheimer’s Disease.” The study received scientific and financial support from a combination of industry, academic, patient‑advocacy, and government partners, including AbbVie Inc., Alzheimer’s Association, Diagnostics Accelerator at the Alzheimer’s Drug Discovery Foundation, Biogen, Janssen Research & Development, and Takeda Pharmaceutical Company Limited. Private‑sector funding was managed by the Foundation for the National Institutes of Health. Statistical analyses were supported in part by National Institute on Aging grant R01AG070941. Data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) were also used.
Editorial Notes
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full.
- Additional context was added by staff.
About this Alzheimer’s disease research news
Author: Jessica Church
Source: WUSTL
Contact: Jessica Church, WUSTL
Image: Image credited to Neuroscience News
Abstract
Predicting onset of symptomatic Alzheimer’s disease with plasma p-tau217 clocks
Predicting not just whether, but when cognitively unimpaired individuals are likely to develop Alzheimer’s disease symptoms would aid clinical trials and, eventually, clinical practice. While clock models using amyloid and tau PET imaging have shown promise, a plasma-based model would be more accessible. Using longitudinal plasma %p-tau217 from two independent cohorts (n = 258 and n = 345), clock models estimated the age at plasma %p-tau217 positivity. That estimated age was associated with age at symptom onset with adjusted R2 values between 0.337 and 0.612 and a median absolute error of 3.0–3.7 years. The interval from %p-tau217 positivity to symptom onset was substantially shorter in older individuals. Similar models were constructed using multiple p-tau217 assays. These findings indicate that symptom onset timing can be estimated from a single blood test with sufficient accuracy for use in clinical trials.